


Lung Cancer Diagnostics

An estimated 238,340 new cases of lung cancer are expected to be diagnosed in 2023 within the United States.¹

Lung cancer is divided into two main subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Up to 85% of all lung cancers are NSCLC, which can be further subtyped into adenocarcinoma, squamous cell carcinoma and large cell carcinoma.² Now more than ever, there's a need for accurate classification of the subtypes for new targeted therapies.

Roche is committed to the development of innovative tools to better diagnose and subtype lung cancer – so labs can deliver the right result with diagnostic confidence. Our portfolio contains gold-standard, peer-reviewed clones like p40 (BC28) and VENTANA ALK (D5F3) CDx Assay, and continues to expand with our rich pipeline of analytical biomarkers and companion diagnostic assays, like VENTANA PD-L1 (SP263) Assay and VENTANA PD-L1 (SP142) Assay. [Learn more.](#)



References:

1. National Cancer Institute (2023). Cancer Stat Facts: Lung and Bronchus Cancer. <https://seer.cancer.gov/statfacts/html/lungb.html>. Accessed 2 June 2023.
2. American Cancer Society (2023). What is Non-Small Cell Lung Cancer? <https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html>. Accessed 2 June 2023.